Adaptive Biotechnologies (ADPT)
(Real Time Quote from BATS)
$2.58 USD
0.00 (0.00%)
Updated Apr 24, 2024 02:48 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Price, Consensus and EPS Surprise
ADPT 2.58 0.00(0.00%)
Will ADPT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ADPT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ADPT
Exploring Analyst Estimates for Adaptive Biotechnologies (ADPT) Q4 Earnings, Beyond Revenue and EPS
Adaptive Biotechnologies (ADPT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
ADPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Prothena (PRTA) Soars 18.7%: Is Further Upside Left in the Stock?
Strength Seen in Adaptive Biotechnologies (ADPT): Can Its 9.5% Jump Turn into More Strength?
Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Tops Revenue Estimates
Other News for ADPT
Netflix, ON Semiconductor And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Why Wang & Lee Group Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
BTIG Sticks to Their Buy Rating for Adaptive Biotechnologies (ADPT)